Business Description
Antibe Therapeutics Inc
NAICS : 541710
SIC : 3741
ISIN : CA0370251039
Description
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-Revenue | 19.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antibe Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.241 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -35.58 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.44 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.44 - 2.44 | ||
| Shares Outstanding (Mil) | 53.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Antibe Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Antibe Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2020-12-01 | 2.44 (-3.17%) |
Show
Entries
Antibe Therapeutics Inc Frequently Asked Questions
What is Antibe Therapeutics Inc(STU:4B70)'s stock price today?
The current price of STU:4B70 is €2.44. The 52 week high of STU:4B70 is €2.44 and 52 week low is €2.44.
When is next earnings date of Antibe Therapeutics Inc(STU:4B70)?
The next earnings date of Antibe Therapeutics Inc(STU:4B70) is .
Does Antibe Therapeutics Inc(STU:4B70) pay dividends? If so, how much?
Antibe Therapeutics Inc(STU:4B70) does not pay dividend.
Press Release
Articles on Antibe Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers